MOTS-c: a mitochondrial peptide, mostly in mice

Plain-language summary

MOTS-c is a tiny peptide encoded inside mitochondrial DNA that got a lot of attention for metabolism and exercise biology. In animals, it's been linked to better insulin sensitivity and resistance to diet-induced weight gain, working through AMPK-related energy pathways. The honest status: the exciting results are largely preclinical, and human clinical evidence is thin compared with the incretin drugs.

What was studied

Foundational animal and cellular studies of MOTS-c and metabolic homeostasis—insulin sensitivity, obesity resistance under high-fat-diet conditions, and AMPK-pathway signaling.

Key takeaways

• Preclinical data suggest metabolic benefits, especially under metabolic stress or high-fat diets.
• The proposed mechanism (AMPK-related) fits with exercise-mimetic hypotheses that drive the biohacking interest.
• It's an “emerging” compound—intriguing signal, early evidence.
• Human outcome data lag far behind the animal literature.

Limitations & what we don't know

• The mouse-to-human translational gap is large and unresolved.
• Longevity and body-composition claims online often exceed the published evidence.
• Research-chemical quality control is a real-world risk.
• No large human RCTs comparable to the metabolic drug class.

1. 1.

   The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

   2015 · animal

   Foundational preclinical metabolic paper.